Abstract:N6-methyladenosine (m6A) is one of the most prevalent modifications of mRNAs in eukaryotes. Numerous recent studies have indicated that m6A plays the critical role in multiple physiologic functions and disease processes by regulation of mRNA processing, splicing, translation, and stability. Although the majority of RNA methylation studies focus on mRNAs, little is known whether long-coding RNAs (lncRNAs) are also subject to m6A modification. Therefore, this study aims to identify m6A modified lncRNAs and their functional role in pancreatic cancer. We performed methylated RNA immunoprecipitation (MeRIP) profiling against a focused group of lncRNAs and identified five lncRNA candidates, among which the highly enriched lncRNA was LINC00901. RNA dot blot, m6A RNA methylation quantification detection and in vivo RNA pulldown combined with m6A RNA methylation Western Blot confirmed the m6A modification of LINC00901. Of note, the analysis of TCGA datasets indicated that the high level of LINC00901 is associated with the poor overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients. Consistent with this result, we showed that LINC00901 promotes pancreatic cancer cell growth. Importantly, we identified that YTHDF1 serves as a “reader” of the m6A modified LINC00901 and furthermore, ectopic expression of YTHDF1 causes downregulation of LINC00901, suggesting a role for m6A modification in regulation of LINC00901 expression. Experiments are underway to determine how LINC00901 promotes pancreatic cancer cell growth. Citation Format: Wan-Xin Peng, Liu Yang, Yin-Yuan Mo. N6-Methyladenosine modification of LINC00901 promotes pancreatic cancer progression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4827.

RNA N6-methyladenosine Modification Mediates Downregulation of NR4A1 to Facilitate Malignancy of Cervical Cancer.

Retraction Note: RNA M 6 A Methylation Regulates the Epithelial Mesenchymal Transition of Cancer Cells and Translation of Snail

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

N1-methyladenosine methylation in mRNAs drives bladder cancer progression

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

The Roles of M6a RNA Modifiers in Human Cancer

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

The potential role of RNA N6-methyladenosine in Cancer progression

N6‐Methyladenosine Regulates Cilia Elongation in Cancer Cells by Modulating HDAC6 Expression

N6-methyladenine modification in noncoding RNAs and its function in cancer

RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming

Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy

N6-methyladenosine links RNA metabolism to cancer progression

Function of N6-Methyladenosine Modification in Tumors

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

Role of N6-methyladenosine RNA modification in cancer

METTL3's role in cervical cancer development through m6A modification